Avicanna Initiates Comprehensive Cannabis Research Study
Avicanna Launches Groundbreaking Cannabis Study
Avicanna Inc. is stepping into the spotlight with an ambitious new initiative focused on medical cannabis research. This initiative, a large-scale study utilizing the MyMedi.ca platform, aims to explore the real-world effects of cannabis on various health conditions, led by renowned expert Hance Clarke, MD, FRCPC, PhD, who serves as the President of The Canadian Pain Society.
Purpose and Goals of the Study
The study is designed as a prospective, non-interventional, observational investigation with a target enrollment of 1,000 patients. The goal is to assess the therapeutic potential of medical cannabis and its impact on pain, sleep disturbances, anxiety, depression, and epilepsy. Through this study, Avicanna will strive to gather crucial data on how cannabis products can aid in alleviating these health issues.
Doctor's Perspective
Dr. Hance Clarke expresses enthusiasm about Avicanna's commitment to this significant research endeavor, emphasizing the need to collect data on cannabis's effects on patients seeking therapeutic benefits. By gathering this evidence, the study aims to enhance understanding and inform future treatments.
MyMedi.ca: A Platform for Patient Support
The MyMedi.ca platform, a focal point of this study, was designed to improve access to medical cannabis, provide education and support, and facilitate research in the cannabinoid sector. Dr. Karolina Urban, Executive Vice President of Medical Affairs, highlighted the platform's role in supporting the study and disseminating findings that could ultimately shape standards of care for a variety of health conditions.
Commitment to Ongoing Research
This study follows a previous initiative launched by Medical Cannabis by Shoppers, which emphasizes Avicanna's dedication to patient care and medical advancement. By leveraging MyMedi.ca, Avicanna is providing substantial support to healthcare professionals and patients alike, establishing a foundation for continued research in cannabinoid medicines.
Patient Involvement and Product Access
Patients participating in this comprehensive study will gain access to various products available through the MyMedi.ca platform, including Avicanna's exclusive RHO Phyto formulary, alongside offerings from select licensed producers participating in the study. This presents a unique opportunity for patients to explore tailored cannabis solutions that meet their specific needs.
About Avicanna Inc.
Avicanna Inc. is an innovative biopharmaceutical company with a global focus on developing and commercializing cannabinoid-based products. With a robust research and development background, Avicanna has successfully commercialized over thirty proprietary products backed by scientific evidence. They operate through a comprehensive business model that encompasses various stages of cannabis product development.
Key Offerings by Avicanna
Among the significant offerings is the RHO Phyto medical cannabis formulary, featuring diverse products designed to meet different patient preferences. The platform also includes the MyMedi.ca model, which specializes in enhancing the patient experience and aiding healthcare professionals in integrating cannabis into their practices.
Future Directions and Innovations
Avicanna continues to develop its pharmaceutical pipeline, including indication-specific products aimed at addressing unmet medical needs in areas like dermatology, chronic pain, and neurological conditions. Notably, Trunerox™, Avicanna’s first indication-specific product, has recently received approval from Health Authority of Colombia for specific types of seizures.
Frequently Asked Questions
What is the objective of the study launched by Avicanna?
The study aims to evaluate the therapeutic effects of medical cannabis on conditions like pain, anxiety, and epilepsy among 1,000 enrolled patients.
Who is leading the research study?
The study is led by Dr. Hance Clarke, a well-respected figure in the field of pain management and cannabis research.
How does the MyMedi.ca platform support patients?
MyMedi.ca provides access to medical cannabis products, patient education, and healthcare professional support, enhancing the overall patient experience.
What products are available through the study?
Participants will have access to Avicanna’s RHO Phyto products and offerings from select licensed producers involved in the study.
What other initiatives does Avicanna have for medical research?
Avicanna is continuously developing its product pipeline and aims to incorporate real-world evidence to shape the future of cannabinoid-based treatments.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Kessler Topaz Initiates Class Action Lawsuit Against Bumble Inc.
- GPM Initiates Investigation into Sun Communities, Inc. (SUI) for Investors
- Nyxoah's DREAM Study Shows Promising Results for OSA Treatment
- Cannabis Sector Market Movement: Gains and Losses Overview
- Orange Initiates Share Buyback Program for Long-Term Incentives
- New York's Cannabis Market Expected to Surge to $1 Billion
- Cannabis Gifting Landscape Faces Uncertain Regulations Ahead
- New Senate Bill Seeks Comprehensive Regulation of Hemp Products
- Westgold Resources Unveils Comprehensive Technical Report
- Bristol Myers Squibb Unveils Promising Sotyktu Study Results
Recent Articles
- Goliath Resources Limited's Upcoming Presentation at Virtual Conference
- Alibaba and Nvidia Join Forces to Transform EV Technology
- Ipsen Secures EU Approval for Kayfanda to Treat Rare Liver Condition
- AGF Investments Details Cash Distributions for Upcoming ETFs
- AGF Investments Reveals Important Cash Distribution Details
- Explore Top Health Care Stocks Poised for Growth
- Mouawad and OCTA Properties Launch Luxurious Residences
- StandardAero's Initial Public Offering: Key Insights and Details
- Exciting Developments from Capital Square's Newest Opportunity Zone Funds
- Microsoft Faces Competition After Downgrade from D.A. Davidson
- SolarBank's Innovative 5.4 MW Community Solar Initiative
- BE Semiconductor Faces Challenges as HSBC Lowers Outlook
- FPX Nickel Strengthens Leadership for Baptiste Project Growth
- C2C Metals Corp. Expands Uranium Prospects with New Claims
- StandardAero Eyes $7.5 Billion Valuation with Upcoming IPO
- Boeing Faces Delivery Setbacks Amid Worker Strike Challenges
- Luca Mining Corp. Secures Strong Funding with C$11.3M
- Exploration Successes at Kaycee Project: Extended Mineralization
- Bank of America's Strategic Branch Expansion Through 2026
- LiTHOS Group Limited Reports Advancements in Lithium Tech
- General Motors Faces Downgrade Amid Rising Earnings Risks
- TriSalus Life Sciences Unveils Advanced Liver Tumor Treatment
- Mural Oncology Welcomes Sachiyo Minegishi to Its Board
- i3 Verticals Sells Merchant Services for $438 Million
- SSR Mining's Seabee Operations Set to Reopen Soon
- Invivyd Inc. Advances in COVID-19 Antibody Research
- Repare Therapeutics Unveils Major Insights on Cancer Biomarkers
- uniQure's FDA Orphan Drug Status Boosts Fabry Disease Therapy
- New Head and Neck Oncologist Joins Karmanos Cancer Institute
- Bank of America Plans to Launch 165 New Financial Centers by 2026
- Tonix Pharmaceuticals Unveils Breakthrough in Fibromyalgia Care
- INEOS Quattro Finance 2 Plc Offers Tender for Senior Notes 2024
- Apellis Pharmaceuticals Faces Review Setback: Market Adjusts Ratings
- Kering Faces Luxury Market Challenges Amid Price Target Cut
- Fed's Kashkari Applauds Recent Interest Rate Cuts for Recovery
- Current Trends in Bitcoin, XRP, and Ethereum: Market Insights
- Bybit Türkiye Achieves CMB Listing as a Trusted Crypto Provider
- Nvidia Approaches Critical Decision Point for Future Growth
- Understanding Discounts in CEFs: A Key to Smart Investing
- Exploring The Future of Electronic Data Interchange by 2031
- Armanino Foods Joins OTCQX: A New Chapter for Investors
- Maquia Capital Makes Promising Debut on OTCQX Trading Market
- Troilus Gold Expands Renewable Energy Solutions for Sustainability
- Kamada Expands Plasma Collection with New Houston Center
- Hammond Power Solutions Announces Acquisition of Micron Industries
- Exploring lululemon's Insights on Global Wellbeing Trends
- Promising Phase 2 Data for BDTX-1535 in NSCLC Patients
- Innovative Insights on Esophageal Cancer Risks from Castle Biosciences
- Passage Bio Highlights the Future of Genetic Medicine in Conference
- Hedge Fund Strategies Shift Towards Tech Amid Rate Cuts